Skip to main content
Premium Trial:

Request an Annual Quote

USPTO Publishes Three RNAi-Related Patent Applications: Jul 10, 2008

Premium
Title: Method and Substances for Isolating miRNAs
 
Number: 20080160511
 
Filed: Aug. 18, 2006 PCT Filed: Aug. 18, 2006
 
Lead Inventor: Elliott Dawson, BioVentures
 
The patent application, its abstract states, claims “a capture probe suitable for use with a method for isolating miRNAs,” as well as the method itself.
 

 
Title: RNA Interference-Mediated Inhibition of Gene Expression Using Short Interfering Nucleic Acid
 
Number: 20080161256
 
Filed: Aug. 17, 2005
 
Lead Inventor: David Morrisey, Sirna Therapeutics (Merck)
 
The invention, according to the patent application’s abstract, “relates to compounds, compositions, and methods useful for modulating gene expression using short interfering nucleic acid molecules. In particular, the instant invention features small nucleic acid molecules … and methods used to modulate the expression of genes, such as expressed pseudogenes associated with the maintenance or development of diseases, disorders, traits, and conditions in a subject or organism. The invention also provides small nucleic acid molecules with reduced or attenuated immunostimulatory properties and methods for designing and synthesizing such small nucleic acid molecules having improved toxicologic properties while retaining RNAi activity.”
 

 
Title: siRNA Targeting Serine/Threonine Protein Kinase AKT
 
Number: 20080161547
 
Filed: July 23, 2007
 
Lead Inventor: Anastasia Khvorova, Dharmacon (Thermo Fisher Scientific)
 
“Efficient sequence-specific gene silencing is possible through the use of siRNA technology,” the patent application’s abstract states. “By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene-silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to an AKT protein.”

The Scan

Rise of BA.5

The New York Times reports that the Omicron subvariant BA.5 has become the dominant version of SARS-CoV-2 in the US.

UK Health Secretary Resigns

Sajid Javid, the UK health secretary, resigned along with Chancellor Rishi Sunak, saying they cannot work with Prime Minister Boris Johnson's government, CNN reports.

Clones From Freeze-Dried Cells

A team in Japan has cloned mice from freeze-dried skin cells, according to the Guardian.

Genome Research Papers on Craniosynostosis, Macaque Retrotransposition, More

In Genome Research this week: structural variants in craniosynostosis, LINE-1 activity in rhesus macaque brain, and more.